Compare ACM Research Inc (ACMR) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Sanofi SA — how do they compare? ACM Research Inc trades at $98.07 (market cap $6.54B), while Sanofi SA trades at $42.85 (market cap $103.29B). The key difference: Sanofi SA is far larger — about 15.8× ACM Research Inc's market cap, and Sanofi SA pays a 5.63% dividend while ACM Research Inc pays none. Which is the better fit depends on your goals.
| ACMR | SNY | |
|---|---|---|
Market Cap | $6.54B | $103.29B |
Sector | Technology | Health |
52-Week High | $126.89 | $52.34 |
52-Week Low | $23.92 | $41.33 |
Enterprise Value | $5.61B | $119.78B |
Dividend Yield | — | 5.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
SNY trades at $42.98, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results with EPS of $1.10 beating expectations of $1.06, continuing a trend of positive surprises. Revenue grew to $46.72 billion in 2025 with net income margin improving to 16.72%. Recent developments include EU approval for Cenrifki in multiple sclerosis and FDA approval for Tzield expansion in pediatric diabetes treatment.
SNY presents a mixed investment case with solid fundamentals offset by technical weakness. The stock trades at reasonable valuations (P/E 18.9, P/S 1.92) with strong profitability metrics, but faces near-term headwinds from an antitrust probe and bearish technical indicators. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism amid regulatory uncertainties and pipeline execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
